Ustekinumab – Treatment for Plaque Psoriasis

 
Key Data:
Drug (brand/generic)
Ustekinumab (CNTO 1275)
Company/licensee
Centocor and Janssen-Cilag
Therapy class
MAb
Product description
Human anti-IL-12 and anti-IL-23 MAb
Current indication
Moderate-to-severe plaque psoriasis
Market sector
Dermatology
Development status
Pre-registration US and Europe



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development